Life Sciences Tools & Services
12 companies under coverage.
Life Sciences Tools & Services
Bio-Techne Corp (TECH)
At roughly $71, on the engine's base earnings near $2.01 the stock trades close to a mid-thirties forward multiple. That price says the market expects biopharma R&D and bioprocessing demand to normalise to…
Danaher Corporation (DHR)
HOLD. 12-month probability-weighted target $194 (-5% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.
Mettler-Toledo International Inc (MTD)
HOLD. 12-month probability-weighted target $1246 (-6% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.
Agilent Technologies Inc (A)
SELL. 12-month probability-weighted target $133 (-10% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.
Medpace Holdings Inc (MEDP)
SELL. 12-month probability-weighted target $529 (-10% vs spot). P/E Multiple explains 62% of Monte Carlo outcome variance.
Waters Corporation (WAT)
SELL. 12-month probability-weighted target $365 (-9% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.
Illumina Inc (ILMN)
SELL. 12-month probability-weighted target $187 (-11% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.
Thermo Fisher Scientific Inc (TMO)
SELL. 12-month probability-weighted target $512 (-15% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.
Bio-Rad Laboratories Inc (BIO)
SELL. 12-month probability-weighted target $299 (-21% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.
Charles River Laboratories (CRL)
SELL. 12-month probability-weighted target $209 (-26% vs spot). P/E Multiple explains 49% of Monte Carlo outcome variance.
IQVIA Holdings Inc (IQV)
SELL. 12-month probability-weighted target $189 (-27% vs spot). Gross Margin explains 48% of Monte Carlo outcome variance.
Avantor Inc (AVTR)
SELL. 12-month probability-weighted target $11 (-30% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.